157 related articles for article (PubMed ID: 28948577)
1. Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma.
Kendler DB; Araújo ML; Alencar R; de Souza Accioly MT; Bulzico DA; de Noronha Pessoa CC; Accioly FA; de Farias TP; Lopes FPPL; Corbo R; Vaisman M; Vaisman F
Endocrine; 2017 Dec; 58(3):474-480. PubMed ID: 28948577
[TBL] [Abstract][Full Text] [Related]
2. Expression of somatostatin receptor subtype 2 and subtype 5 in thyroid malignancies.
Woelfl S; Bogner S; Huber H; Salaheddin-Nassr S; Hatzl M; Decristoforo C; Virgolini I; Gabriel M
Nuklearmedizin; 2014; 53(5):179-85. PubMed ID: 24967740
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma.
Mato E; Matías-Guiu X; Chico A; Webb SM; Cabezas R; Berná L; De Leiva A
J Clin Endocrinol Metab; 1998 Jul; 83(7):2417-20. PubMed ID: 9661621
[TBL] [Abstract][Full Text] [Related]
4. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
[TBL] [Abstract][Full Text] [Related]
5. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I
Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors.
Kölby L; Wängberg B; Ahlman H; Tisell LE; Fjälling M; Forssell-Aronsson E; Nilsson O
World J Surg; 1998 Jul; 22(7):679-83. PubMed ID: 9606281
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
Vainas I; Koussis Ch; Pazaitou-Panayiotou K; Drimonitis A; Chrisoulidou A; Iakovou I; Boudina M; Kaprara A; Maladaki A
J Exp Clin Cancer Res; 2004 Dec; 23(4):549-59. PubMed ID: 15743023
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
9. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis.
Herac M; Niederle B; Raderer M; Krebs M; Kaserer K; Koperek O
APMIS; 2016 Oct; 124(10):839-45. PubMed ID: 27539746
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt.
Zatelli MC; Tagliati F; Taylor JE; Rossi R; Culler MD; degli Uberti EC
J Clin Endocrinol Metab; 2001 May; 86(5):2161-9. PubMed ID: 11344221
[TBL] [Abstract][Full Text] [Related]
11. In vivo somatostatin receptor imaging in medullary thyroid carcinoma.
Kwekkeboom DJ; Reubi JC; Lamberts SW; Bruining HA; Mulder AH; Oei HY; Krenning EP
J Clin Endocrinol Metab; 1993 Jun; 76(6):1413-7. PubMed ID: 8501144
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility.
Nasir A; Stridsberg M; Strosberg J; Su PH; Livingston S; Malik HA; Kelley ST; Centeno BA; Coppola D; Malafa ME; Yeatman TJ; Kvols LK
Cancer Control; 2006 Jan; 13(1):52-60. PubMed ID: 16508627
[TBL] [Abstract][Full Text] [Related]
13. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer.
Faggiano A; Grimaldi F; Pezzullo L; Chiofalo MG; Caracò C; Mozzillo N; Angeletti G; Santeusanio F; Lombardi G; Colao A; Avenia N; Ferolla P
Endocr Relat Cancer; 2009 Mar; 16(1):225-31. PubMed ID: 19004986
[TBL] [Abstract][Full Text] [Related]
14. Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer.
Qiu CZ; Wang C; Huang ZX; Zhu SZ; Wu YY; Qiu JL
World J Gastroenterol; 2006 Apr; 12(13):2011-5. PubMed ID: 16610049
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of PET/CT with
Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
[TBL] [Abstract][Full Text] [Related]
16. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
[TBL] [Abstract][Full Text] [Related]
18. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma.
Parra-Robert M; Orois A; Augé JM; Halperin I; Filella X; Molina R
Clin Chem Lab Med; 2017 Mar; 55(3):441-446. PubMed ID: 27754959
[TBL] [Abstract][Full Text] [Related]
19. Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies.
Yeh T; Yeung M; Sherman EJ; Tuttle RM; Sabra MM
Thyroid; 2020 Aug; 30(8):1112-1119. PubMed ID: 32131709
[No Abstract] [Full Text] [Related]
20. Somatostatin receptor expression in non-medullary thyroid carcinomas.
Pazaitou-Panayiotou K; Tiensuu Janson E; Koletsa T; Kotoula V; Stridsberg M; Karkavelas G; Karayannopoulou G
Hormones (Athens); 2012; 11(3):290-6. PubMed ID: 22908061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
